RE:RE:RE:RE:RE:RE:RE:RE:Been here a while lurking Gebremeskel ... Again, excellent post. All possible scenario.
The only thing that makes me consider another scenario is the fact that Roger and Kristina invested with their own money back in May and also again participated in the Sept. pp, with Dr. Mandel. Kind of like if they've been reassured by the FDA of not to worry that much about the first 12 patients if the other 13 are have quite convincing results like Ph. 1b p#5-6. Also considering that NML results are planned for Q4. Add also the fact that on Feb. 7, day of the NML news, they also updated their corporate presentation to advance by 30 months "commercial revenues (projected)", which can only come with Accelerated Approval. And we know that we satisfy the criterias of the AA program. And with our 1-2 doses treatment, mixed with low side-effects and high efficacy, and no dependance to BCG (no need to combo) at a time there's still a BCG shortage, the FDA cannot ignore us. Not to mention NML for an anti-COVID-19 vaccine, knowing the tiny little dose required (nanomolar) to kill the COVID-19 virus within seconds. And that decided to move forward with GLP toxicology testing for NSCLC and GBM with Rutherrin.
So it really sounds like something very positive. So the small pp to bridge over a pivotal event, as you say.